Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells 77,587 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) insider John Paolini sold 77,587 shares of the firm’s stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $93.02, for a total transaction of $7,217,142.74. Following the completion of the transaction, the insider directly owned 69,922 shares in the company, valued at $6,504,144.44. This trade represents a 52.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Trading Up 2.7%

Shares of KNSA traded up $2.49 on Tuesday, reaching $93.29. 1,021,631 shares of the company’s stock were exchanged, compared to its average volume of 705,858. The stock has a market capitalization of $7.28 billion, a P/E ratio of 71.76 and a beta of 0.04. The business has a 50 day moving average price of $79.39 and a two-hundred day moving average price of $60.29. Kiniksa Pharmaceuticals International, plc has a 12 month low of $37.02 and a 12 month high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. Equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.26 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Curry Webb Wealth Management LLC acquired a new stake in Kiniksa Pharmaceuticals International in the third quarter worth $29,000. Allworth Financial LP boosted its position in shares of Kiniksa Pharmaceuticals International by 42.0% during the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock worth $29,000 after purchasing an additional 134 shares in the last quarter. Nykredit A S acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $34,000. KBC Group NV acquired a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at $34,000. Finally, USA Financial Formulas acquired a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at $69,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group increased their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Citigroup lifted their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Wells Fargo & Company upped their price objective on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Finally, Wedbush increased their target price on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a research note on Wednesday, October 28th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $100.57.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.